GlycoMimetics amends merger; $200M financing now pre-closing Crescent securities

CRESCENT BIOPHARMA, INC.

Ownership split unchanged: GLYC holders ~3.10%, Crescent ~96.90% after close.
Exchange ratio ~14.9149 Crescent shares per GLYC share; based on Sep 30 caps.
A&R Purchase Agreement: $200M Crescent securities purchased pre-closing, replacing post-closing GLYC financing.
Amendment adjusts filings; S-4 registration statement and company stockholder approval sequence updated.
Condition: GLYC net cash at closing must be ~$1.8M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.